Morgan Stanley Reiterates Equal-Weight on Bicycle Therapeutics, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Equal-Weight rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a $42 price target.
August 04, 2023 | 4:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Bicycle Therapeutics and maintained a $42 price target.
The news is directly about Bicycle Therapeutics. Morgan Stanley's reiteration of an Equal-Weight rating and maintenance of a $42 price target suggests that they believe the stock is fairly valued at its current price. This is likely to have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100